Hypertension remains one of the leading risk factors for cardiovascular disease worldwide, affecting over one billion people and contributing to stroke, myocardial infarction, and renal failure. While multiple pathways regulate vascular tone and blood pressure, endothelin-1 (EDN1) has emerged as one of the most potent endogenous vasoconstrictors. Understanding how EDN1 influences vascular homeostasis provides not only mechanistic insights into hypertension but also novel therapeutic opportunities.
Endothelin-1: A Master Regulator of Vascular Tone
EDN1 is a 21-amino acid peptide predominantly produced by vascular endothelial cells. It acts in a paracrine manner, binding to two G-protein-coupled receptors ETA and ETB located on smooth muscle cells and endothelial cells.
ETA receptor activation leads to sustained vasoconstriction and proliferation of vascular smooth muscle cells.
ETB receptor activation has dual roles: on endothelial cells, it promotes vasodilation via nitric oxide (NO) and prostacyclin release; on smooth muscle cells, it also mediates vasoconstriction.
The balance between these receptor pathways is critical. In hypertensive states, EDN1 levels are elevated, and the balance tips toward excess ETA signaling, resulting in enhanced vascular resistance and elevated blood pressure.
Mechanisms Linking EDN1 to Hypertension
Several mechanisms explain the pathogenic role of EDN1 in hypertension:
- Endothelial Dysfunction: Overproduction of EDN1 disrupts the delicate equilibrium between vasodilation and vasoconstriction.
- Oxidative Stress: EDN1 stimulates reactive oxygen species (ROS) generation, impairing nitric oxide bioavailability.
- Vascular Remodeling: Chronic EDN1 exposure drives smooth muscle proliferation, fibrosis, and arterial stiffening.
- Renal Effects: EDN1 modulates sodium and water reabsorption in the kidney, directly influencing blood pressure regulation.
These combined effects make EDN1 a central mediator in both the initiation and progression of hypertension.
Therapeutic Targeting of the Endothelin Pathway
The recognition of EDN1’s role in hypertension has led to the development of endothelin receptor antagonists (ERAs).
Selective ETA antagonists (e.g., ambrisentan) block vasoconstrictive and proliferative effects.
Dual ETA/ETB antagonists (e.g., bosentan, macitentan) provide broader inhibition but may also interfere with protective ETB-mediated vasodilation.
Although ERAs have been particularly successful in pulmonary arterial hypertension (PAH), their use in systemic hypertension is under ongoing investigation. The main challenges remain side effects such as fluid retention and hepatotoxicity, as well as identifying patient populations that would benefit most.
Emerging Directions in EDN1-Targeted Research
Recent advances are reshaping how we approach EDN1 in hypertension:
Biologics and RNA-based therapies targeting EDN1 synthesis at the transcriptional or post-transcriptional level.
Combination therapies integrating ERAs with ACE inhibitors, ARBs, or calcium channel blockers for synergistic effects.
Personalized medicine approaches leveraging biomarkers of EDN1 activity to predict therapeutic response.
Moreover, organ-on-chip systems and 3D vascular models are providing physiologically relevant platforms to study EDN1 signaling and test novel drugs in preclinical stages.
Conclusion
Endothelin-1 plays a central role in the pathophysiology of hypertension by driving vasoconstriction, endothelial dysfunction, and vascular remodeling. While therapies targeting the endothelin pathway are already transforming the management of pulmonary hypertension, their application in systemic hypertension holds great promise. Continued research into EDN1 biology, advanced therapeutic design, and precision medicine will pave the way for more effective treatments, ultimately reducing the global burden of hypertension.